Pre-Commercial Biopharma Sought to Acquire a LateStage Pipeline Asset in Order to Build a Commercial
Infrastructure in Support of Its First Product Launch
A pre-commercial biopharma company with a robust pipeline of rare
disease assets–the majority in Phase 1 clinical trials–sought to establish a
comprehensive commercialization infrastructure in preparation for their
initial product launch. This foundation and framework were intended to
support future commercialization of the company’s other pipeline assets
and to maximize the value of each asset.
The early-stage biopharma company was actively exploring business
development opportunities for assets that would allow them to come to
market sooner than their current pipeline assets. They were in the final
stages of negotiations and needed to understand what it would take to
commercialize the asset, create a plan that instilled stakeholder
confidence in their ability to successfully commercialize their first asset,
and build an infrastructure to support future pipeline assets.